Clinical Trials
349
Trial Phases
5 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (246 trials with phase data)โข Click on a phase to view related trials
A Study of JNJ-77242113 for the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis
- Conditions
- Erythrodermic PsoriasisGeneralized Pustular Psoriasis
- Interventions
- First Posted Date
- 2024-03-06
- Last Posted Date
- 2025-07-18
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 19
- Registration Number
- NCT06295692
- Locations
- ๐ฏ๐ต
JR Sapporo Hospital, Hokkaido, Japan
๐ฏ๐ตIchinomiya Municipal Hospital, Ichinomiya, Japan
๐ฏ๐ตTeikyo University Hospital, Itabashi Ku, Japan
A Study of AAV5-hRKp.RPGR for the Treatment of Japanese Participants With X-linked Retinitis Pigmentosa
- Conditions
- X-Linked Retinitis Pigmentosa
- First Posted Date
- 2023-07-03
- Last Posted Date
- 2025-07-18
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 4
- Registration Number
- NCT05926583
- Locations
- ๐ฏ๐ต
National Hospital Organization Tokyo Medical Center, Meguro-ku, Japan
A Study of Erdafitinib Intravesical Delivery System in Japanese Participants With Bladder Cancer
- Conditions
- Urinary Bladder NeoplasmsReceptors, Fibroblast Growth Factor
- Interventions
- First Posted Date
- 2022-10-05
- Last Posted Date
- 2025-07-18
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 5
- Registration Number
- NCT05567185
- Locations
- ๐ฏ๐ต
St Marianna University Hospital, Kanagawa, Japan
๐ฏ๐ตOsaka International Cancer Institute, Osaka City, Japan
๐ฏ๐ตToyama University Hospital, Toyama-shi, Japan
A Study of Adenovirus Serotype 26.Respiratory Syncytial Virus.Pre-Fusion F (Ad26.RSV.preF)-Based Vaccine for Prevention of Respiratory Syncytial Virus (RSV) Mediated- Lower Respiratory Tract Disease (LRTD) in Japanese Participants
- Conditions
- Respiratory Syncytial Virus Prevention
- Interventions
- Biological: Ad26/protein preF RSV VaccineOther: Placebo
- First Posted Date
- 2022-02-16
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 2192
- Registration Number
- NCT05242432
- Locations
- ๐ฏ๐ต
Shohokai Toda Internal Medicine and Neurology Clinic, Akashi-shi, Japan
๐ฏ๐ตMedical Corporation JR Hiroshima Hospital, Hiroshima-shi, Japan
๐ฏ๐ตSeikokai Omi Medical Center, Kusatsu-shi, Japan
A Study of Macitentan in Japanese Pediatric Participants With Pulmonary Arterial Hypertension
- First Posted Date
- 2021-12-22
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 7
- Registration Number
- NCT05167825
- Locations
- ๐ฏ๐ต
Nagano Children's Hospital, Azumino-shi, Japan
๐ฏ๐ตInstitute of Science Tokyo Hospital, Bunkyo ku, Japan
๐ฏ๐ตFukuoka Children's Hospital, Fukuoka, Japan
- Prev
- 1
- 2
- 3
- 4
- 5
- 26
- Next